A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE3
TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
- Status
- COMPLETED
- Phase
- PHASE2
OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
- Status
- COMPLETED
- Phase
- PHASE2
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
- Status
- RECRUITING
- Phase
- PHASE1
A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE1
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE3
Azacitidine and Pembrolizumab in Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With Chemotherapy in Refractory MDS
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
- Status
- TERMINATED
- Phase
- PHASE1
Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage
- Status
- COMPLETED
- Phase
- PHASE1
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3